GLP-1 Agonists: Beyond Diabetes and Weight Loss, Protecting Heart and Kidneys

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of incretin analogues (hormone-like substances that stimulate insulin release) widely used for managing type 2 diabetes mellitus and obesity. These compounds work by mimicking natural GLP-1, promoting glucose-dependent insulin release and offering multiple metabolic benefits. While their efficacy in glucose control and weight reduction is well-established, recent large-scale trials have also revealed significant cardiovascular and renal protective effects. However, questions persist regarding long-term adherence, potential weight regain post-treatment, and the functional implications of observed muscle and bone mass loss.

The review confirmed the established efficacy of GLP-1 receptor agonists in promoting glucose-mediated insulin release and achieving significant weight loss through multiple mechanisms. These include a reduction in gastric emptying, inhibition of glucagon secretion, beneficial changes in the intestinal microbiome, and direct effects on hypothalamic nuclei to enhance satiety. Crucially, evidence from large-scale randomized, controlled trials consistently demonstrates that these agonists reduce cardiovascular risk and slow the progression to renal failure in high-risk individuals and those with type 2 diabetes. > The most significant finding from the synthesis of existing data is the proven cardiovascular and renal protective effects of GLP-1 receptor agonists, extending their utility beyond glucose control and weight management. The review also noted that while adverse effects are mostly gastrointestinal, concerns remain regarding potential loss of muscle and bone mass. Furthermore, recent and ongoing studies suggest the possibility of additional therapeutic uses for this drug class, highlighting its evolving therapeutic landscape.